Overview

Intra-arterial Albumin in Acute Ischemic Stroke After Endovascular Treatment for

Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
0
Participant gender:
All
Summary
Stroke is an acute focal injury of the central nervous system caused by cerebral vessels. One in every four people is affected by stroke at different times in life. Globally, stroke is the second leading cause of death and third leading cause of disability in adults. we hypothesized that in patients with acute large vessel occlusive ischemic stroke treated with mechanical thrombectomy, the infusion of 20% human serum albumin solution into the revascularization area can exert a stronger neuroprotective effect.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tianjin Huanhu Hospital
Criteria
Inclusion Criteria:

1.Male or female, age≥18 and ≤ 80; 2. anterior circulation large vessel occlusion confirmed
by CTA, MRA and DSA; 3. baseline National Institute of Health Stroke Scale (NIHSS) score
≥6; 4. Alberta Stroke Program Early CT Score (ASPECTS) 6-10; 5. Stroke symptoms present to
femoral artery or brachial artery puncture within 24 hours; 6. occluded vessel reaches
eTICI level ≥2b after thrombectomy confirmed by DSA;7. Informed consent obtained;

Exclusion Criteria:

(1) history of congestive heart failure or jugular dilatation, third heart sound, resting
tachycardia due to heart failure (>100 beats/min), hepatomegaly and lower limb edema
without obvious cause on admission physical examination; (2) hospitalization for acute
myocardial infarction within 3 months; (3) symptoms of acute myocardial infarction or
admission electrocardiogram; (4) second or third degree heart block or arrhythmia with
hemodynamic instability; (5) acute or chronic renal failure (blood creatinine > 2.0 mg/dL);
(6) severe anemia (hematocrit<32%); (7) symptoms or CT evidence of subarachnoid hemorrhage;
(8) pregnancy; (9) allergy to albumin; (10) admission blood pressure higher than 185/110
mmHg; (11) any chronic lung disease, including chronic obstructive pulmonary disease,
bronchiectasis, and other lung diseases that interfere with daily activities; (12) presence
of other diseases that may endanger life.